Optaflu

From Wikipedia, the free encyclopedia

Influenza (Flu)

Types
Avian A/H5N1 subtype Canine Equine Swine A/H1N1 subtype
Vaccines
2009 pandemic Pandemrix Fluzone Influvac Live attenuated Optaflu
Treatment
Amantadine Arbidol Laninamivir Oseltamivir Peramivir Rimantadine Vitamin D Zanamivir
Pandemics
2009 swine 1968–1969 Hong Kong 1957 Asian flu 1918
Outbreaks
2008 West Bengal 2007 Bernard Matthews H5N1 2007 Australian equine 2006 H5N1 India 1976 swine flu
See also
Flu season Influenza evolution Influenza research Influenza-like illness Vaccine reformulations
v t e

Optaflu is a cell culture derived influenza vaccine manufactured by Novartis.

History

On April 27, 2007 Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.^[1] The vaccine will be manufactured in Holly Springs, North Carolina. The United States government is providing $500 million in construction costs and guaranteed vaccine purchases.^[2]

References

↑ "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. Retrieved 2009-04-29.
↑ Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. Retrieved 2009-04-29. "But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases."

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.